Vancouver, British Columbia--(Newsfile Corp. - April 4, 2018) - Altamira Gold Corp. (TSXV: ALTA) (FSE: T6UP) (OTC Pink: EQTRF), ("Altamira" or the "Company") is pleased to report that the Company has claimed significant additional ground within the Juruena belt in Mato Grosso, Brazil. These new clai...Read More
NasoVAX intranasal influenza vaccine demonstrated strong cellular immune response and 100% seroprotection HepTcell vaccine was well tolerated but T-cell immunogenicity results were inconclusive GAITHERSBURG, Md., March 27, 2018 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq:ALT), a clinical-st...Read More
Vancouver, British Columbia--(Newsfile Corp. - February 21, 2018) - Altamira Gold Corp. (TSXV: ALTA) (FSE: T6UP) (USA: EQTRF), ("Altamira" or the "Company") is pleased to report that it commenced an exploration program for concealed porphyry copper mineralization throughout the Juruena Belt of...Read More
GAITHERSBURG, Md., March 22, 2018 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq:ALT), a clinical-stage immunotherapeutics company, announced today that Bill Enright, President and Chief Executive Officer, will provide a corporate overview at H.C. Wainwright Global Life Sciences Conference, being...Read More
GAITHERSBURG, Md., March 20, 2018 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq:ALT), a clinical-stage immunotherapeutics company, today announced that it will announce financial results for the quarter and year ended December 31, 2017 before the market open and host a conference call on Thursda...Read More
Single dose of vaccine showed 67% survival rate and 100% survival rate after two doses GAITHERSBURG, Md., March 12, 2018 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq:ALT), a clinical-stage immunotherapeutics company, today announced data from a pre-clinical study comparing SparVax-L and BioT...Read More
GAITHERSBURG, Md., March 06, 2018 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq:ALT), a clinical-stage immunotherapeutics company, announced today that Bill Enright, President and Chief Executive Officer, will provide a corporate overview at the 30th Annual ROTH Conference and the B. Riley FBR I...Read More
Vancouver, British Columbia--(Newsfile Corp. - February 21, 2018) - Altamira Gold Corp. (TSXV: ALTA) (FSE: T6UP) (USA: EQTRF), ("Altamira" or the "Company") is pleased to report that it commenced an exploration program for concealed porphyry copper mineralization throughout the Juruena Belt of...Read More
Vancouver, British Columbia--(Newsfile Corp. - February 9, 2018) - Altamira Gold Corp. (TSXV: ALTA) (FSE: T6UP) (OTC Pink: EQTRF), ("Altamira" or the "Company") is pleased to provide drill results from the first phase drill program at the Crepori project located in southern Para state, Brazil....Read More
Patent Will Specifically Cover Prophylactic and Post-Exposure Use of NasoShield in the U.S. Patents with Similar Protection Already Issued in Europe and Japan GAITHERSBURG, Md., Jan. 23, 2018 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq:ALT), a clinical-stage immunotherapeutics company, toda...Read More
GAITHERSBURG, Md., Jan. 22, 2018 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq:ALT), a clinical-stage immunotherapeutics company, announced today that Bill Enright, President and Chief Executive Officer, will provide a corporate overview at NobleCon14 - Noble Capital Markets’ Fourteen...Read More
Altamira Reports Trenching Results of 29m @ 3.03g/t Gold at Baldo East Target, Cajueiro Project, Brazil and Extends Structures Vancouver, BC (FSCwire) - Altamira Gold Corp. (TSXV: ALTA) (FSE: T6UP) (USA: EQTRF), (“Altamira” or the “Company”) is pleased to report t...Read More
Current Chairman, David Drutz, M.D., remains Chairman of Compensation Committee and Member of the Board GAITHERSBURG, Md., Jan. 03, 2018 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq:ALT), a clinical-stage immunotherapeutics company, today announced the election of Mitchel Sayare, Ph.D....Read More
HepTcell well tolerated in all cohortsInitial data on secondary endpoint demonstrates T cell responses GAITHERSBURG, Md., Dec. 21, 2017 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq:ALT), a clinical-stage immunotherapeutics company, today announced it has completed dosing of its HepTcell Phase...Read More
GAITHERSBURG, Md., Dec. 21, 2017 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq:ALT), a clinical-stage immunotherapeutics company, announced today that Bill Enright, President and Chief Executive Officer, will provide a corporate overview at the 10th Annual Biotech Showcase, being held January 8-...Read More
Altamira Gold Corp Closes $1,933,000 Non-Brokered Private Placement Not For Distribution to United States Newswire Services nor For Dissemination in the United States Vancouver, BC (FSCwire) - Altamira Gold Corp. (TSXV: ALTA) (FSE: T6UP) (USA: EQTRF), (“Altamira” or the “Com...Read More
(TheNewswire) Toronto, Canada and Lima, Peru / TheNewswire / December 12, 2017 – Alturas Minerals Corp. (the “Company” or “Alturas”) (TSX-V, BVL: ALT) announced today that it has entered into agreements to settle an aggregate of $826,134.24 of debt owed to certa...Read More
145 Patients to be enrolledData expected in the second quarter of 2018Study will be fully-funded by BARDA GAITHERSBURG, Md., Dec. 11, 2017 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq:ALT), a clinical-stage immunotherapeutics company, today announced the Company has submitted an Investi...Read More
GAITHERSBURG, Md., Nov.21, 2017(GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq:ALT), a clinical-stage immunotherapeutics company, today announced that Bill Enright, president and chief executive officer of Altimmune, will present a corporate overview at the 29th Annual Piper Jaffray Conference, takin...Read More
VANCOUVER, Nov. 15, 2017 /CNW/ - The following issues have been halted by IIROC: Company: ALTAMIRA GOLD CORP TSX-Venture Symbol: ALTA Reason: At the Request of the Company Pending News Halt Time (ET): 1:16 PM IIROC can make a decision to impose a temporary suspension (halt) of trading in a s...Read More